CYNAF Stock News 0.5211 05/06/2014 13:16:27 Cynapsus Therapeutic

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cynapsus Therapeutic (CYNAF) 0.5211 $CYNAF

Cynapsus Announces Positive Results of CTH-104 Clinical Study of APL-130277 for Parkinson's Disease
Marketwire - Thu Apr 24, 5:02AM CDT
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced positive data from its recently completed CTH-104 healthy volunteer pilot study of a single 25mg sublingual strip (APL-130277) dose of apomorphine. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug in the United States, Europe, Japan and other countries for the acute rescue of "off" motor symptoms of Parkinson's disease.

Cynapsus Therapeutics Inc. : Cynapsus Announces Positive Results of CTH-104 Clinical Study of APL-130277 for Parkinson's Disease
Thomson Reuters ONE - Thu Apr 24, 5:01AM CDT
April 24, 2014

Cynapsus Announces Interim Summary Results of Human Healthy Volunteer Single 25mg Study for APL-130277
Marketwire - Fri Mar 28, 5:01AM CDT
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced positive interim data from its recently completed healthy volunteer pilot study of a single 25mg sublingual strip (APL-130277) dose of apomorphine. APL-130277 is an easy-to-administer, fast-acting reformulation of apomorphine, which is the only approved drug (in the United States, Europe, Japan and other countries) to rescue patients from "off" episodes. The interim CTH-104 study results indicate that a higher load of drug on the strip does result in a higher amount of drug entering the blood stream.

Cynapsus Therapeutics Inc. : Cynapsus Announces Interim Summary Results of Human Healthy Volunteer Single 25mg Study for APL-130277
Thomson Reuters ONE - Fri Mar 28, 5:00AM CDT
PRESS RELEASE

Cynapsus Therapeutics Reports 2013 Financial Results and Highlights Key Developments
Marketwire - Thu Mar 27, 3:01PM CDT
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company developing a convenient and easy to use sublingual (oral) thin film strip for the acute rescue of "off" motor symptoms of Parkinson's disease, today announced its results for the year ended December 31, 2013. Unless specified otherwise, all amounts are in Canadian dollars.

Cynapsus Therapeutics Announces DTC Approval
Marketwire - Thu Feb 27, 8:24AM CST
Cynapsus Therapeutics Inc. ("Cynapsus" or the "Company" (TSX VENTURE: CTH)(OTCQX: CYNAF) today announced that the common shares of the Company (CUSIP 23257Y701) have been made eligible for book-entry delivery and depository services of The Depository Trust Company (the "DTC" to facilitate electronic settlement of transfers of its common shares in the United States.

Cynapsus Therapeutics Appoints Nan Hutchinson to the Board of Directors
Marketwire - Thu Feb 13, 7:02AM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company with a lead program in Parkinson's disease, today announced the appointment of Nan Hutchinson to the Board of Directors.

LifeSci Advisors Initiates Coverage of Cynapsus Therapeutics, Inc.
Marketwire - Fri Feb 07, 8:15AM CST
LifeSci Advisors, LLC announcement for Cynapsus Therapeutics, Inc. (TSX VENTURE: CTH) (OTCQX: CYNAF)

Cynapsus Therapeutics Announces Exercise of Warrants
Marketwire - Thu Jan 23, 3:01PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced that in January, 125,324 warrants with an exercise price of $0.575 have been exercised for total proceeds of $72,062. Following the exercise of these warrants, Cynapsus has 39,009,335 commons shares, 21,426,439 warrants and 2,691,316 options to purchase common shares outstanding.

Cynapsus Announces Resignation of Chief Scientific Officer
Marketwire - Wed Jan 22, 3:31PM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH)(OTCQX: CYNAF), a specialty pharmaceutical company, today announced that Nathan Bryson, Chief Scientific Officer, will be leaving the Company to pursue other opportunities.

Cynapsus Announces Completion of Human Healthy Volunteer Crossover Study Results for APL-130277
Marketwire - Mon Jan 13, 5:01AM CST
Cynapsus Therapeutics Inc. (TSX VENTURE: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company, today announced positive top line data from its recently completed healthy volunteer pilot crossover trial comparing APL-130277, a sublingual thin film strip formulation of apomorphine, to a commercially available injectable formulation of apomorphine. The study results further support the advancement of APL-130277 for management of "OFF" episodes in Parkinson's disease through the section 505(b)(2) regulations of the United States Food and Drug Administration Act, which provides an accelerated path to approval for new formulations of approved medicines.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 135

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 35

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 20

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Nauticus Robotics Dive into Defense & UAE Moves

Updated Category News Views 78

Charting New Waters: Defense and UAE Focus Looking at Nauticus Robotics lately, it feels like they're finally getting the hang of balancing their defense play and UAE expansions. This quarter they're coming out swinging, dropping some fine numbers mixed with a slew of strategic moves that got me thinking twice about their place in the subsea robotics world. Financial...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 70

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading
Graphic Packaging Shakes Up Leadership and Supply Chain

Updated Category News Views 29

New Leadership Takes the Helm at Graphic Packaging What do you do when you want to streamline an operation that spans continents? Well, if you're Graphic Packaging Holding Company (NYSE: GPK), you bring in fresh leadership to serenade the chaos into a well-oiled machine. Starting December 1, 2026, D. Keith Hamilton will be sinking his teeth into North America Mills &...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 194

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 119

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
ROBOTERA Debuts XHAND 1 Pro-U in NVIDIA Demo

Updated Category News Views 117

ROBOTERA Steps Up with XHAND 1 Pro-U Move over, traditional robotics; ROBOTERA is here to shake things up with their latest marvel, the XHAND 1 Pro-U. This futuristic gadget isn't just making waves at the Conference on Robot Learning (CoRL) where Jim Fan of NVIDIA spotlighted it in his GR00T 2 demo, it's setting a new bar for robotic dexterity. Hand in Glove with Human...

Continue Reading
Saint Luis Rey Launches Exclusive Palatinos Vitola

Updated Category News Views 59

New Beginnings for the Saint Luis Rey Brand You think you've seen it all in the cigar world, but then comes a debut like this that lights a fire under the lush tradition of Cuba. Enter Saint Luis Rey's new Palatinos vitola, a blend wrapped in the mystique of exclusivity for La Casa del Habano and Habanos Specialists. Whether you're a seasoned connoisseur or just dipping...

Continue Reading

Top 5 Most Recently Viewed Articles

Navigating the Rising Tide of AI-Driven Cyber Threats

Updated Category News Views 118

The Evolving Landscape of Cyber Threats In today's world, artificial intelligence is rapidly changing the nature of cyber threats. Recent studies reveal that a significant number of companies have encountered AI-driven cyberattacks, highlighting a critical gap in their defense strategies. Despite this alarming trend, many organizations are yet to fully embrace AI in their...

Continue Reading
Insight into the Bullish Movements Surrounding DPZ Stock

Updated Category News Views 58

Understanding the Options Dynamics for Domino's Pizza Investors are expressing a clear bullish sentiment towards Domino's Pizza as evident from the recent options market activities. Analyzing the options history for Domino's Pizza (DPZ), we found a total of 10 significant trades. These trades reveal that approximately 50% of traders leaned towards bullish strategies while...

Continue Reading
PDD Holdings Faces Legal Challenges Over Securities Violations

Updated Category News Views 230

PDD Holdings Faces Legal Challenges Over Securities Violations PDD Holdings, Inc. is currently facing a major class action lawsuit. This legal action stems from accusations that the company misled investors about potential compromises to its applications, raising serious concerns about user privacy, particularly regarding unauthorized access to private messages. Details...

Continue Reading
Significant Shareholder Announcement for Kenmare Resources

Updated Category News Views 98

Major Holdings Notification for Kenmare Resources Plc Understanding the dynamics of major shareholdings is essential for investors and stakeholders alike. Kenmare Resources Plc has recently updated the market regarding key holdings that affect its share structure. The notification process is transparent, with clear communication ensuring that all relevant details are...

Continue Reading
Exploring High-Yield Dividend Stocks for Income Investors

Updated Category News Views 65

Dive into Dividend Investing Dividend investing is often overlooked, especially in an era dominated by the latest advancements in technology and artificial intelligence. While the allure of tech growth may be tempting, savvy investors understand the enduring value of reliable income-generating stocks. The world of dividend stocks is vast, and their potential for...

Continue Reading